Illegal immunotherapy treatments in China found at military-run hospitals: Reuters

shanghai
Shanghai

Military hospitals in China are offering unapproved immunotherapy and stem cell treatments, Reuters reports, promising miracle cures at steep fees.

The news agency said promising preclinical therapeutics were offered at the military-run hospitals under the noses of regulators with advertisements. An informal survey showed "roughly four-fifths offered some kind of immunotherapy on their websites," Reuters said.

"Some of them said they had used it to treat thousands of patients," according to the report.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

In one case highlighted, 21-year-old patient Wei Zexi died after treatment at the Second Hospital of Beijing Armed Police Corps. The hospital did not respond to requests for comment by Reuters.

China's health ministry investigated the case and found "serious problems" that included the use of "unauthorised clinical technology," Reuters said.

The country's health ministry, however, told Reuters in statement that it still classified immunotherapy as high risk and that no therapies had yet been approved for treatment.

Military hospitals in China stand apart from the state-run hospital system and often provide top-notch care to military members and senior-ranking political leaders, possibly allowing them more freedom from oversight, Reuters said.

China's massive state-run hospital system is under a crushing daily load of patients that sometimes pay touts to get quicker appointments. As well, many doctors run assembly-line operations.

Specialist care in areas like cancer, the biggest killer in China, is in short supply, though key military hospitals do have better facilities and doctors in many cases.

According to Reuters, citing Jones Day law firm partner Yuan Liming, some of the care at the military hospitals comes from third parties operating clinics for certain therapies in violation of health ministry rules.

Reuters said Wei's case centered on such a third-party service, immunotherapy technology company Shanghai Claison, which did not respond to requests for comment.

- here's the story from Reuters

Related Articles:
Touts thwart top-level reforms at China's public hospitals

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.